Mitigation of the SARS-CoV-2 pandemic will continue to require innovative solutions. This webinar will outline how Fry Laboratories rapidly redeployed a next-generation sequencing (NGS) pipeline originally created for the detection and identification of bacterial, eukaryotic, and fungal infections in response to SARS-CoV-2.
NGS offers unbiased microbial detection while leveraging the analytical and cost-effectiveness advantages of PCR-based methods. This represents a relatively untapped resource, but the approach creates several unique implementation challenges and solutions.
In this webinar, Jeremy Ellis of Fry Laboratories will describe an ultra-high-throughput SARS-CoV-2 detection assay for as many as 1,152 saliva samples using a single MiSeq Micro flow cell. The assay uses PCR to simultaneously amplify, index, and adapt SARS-CoV-2 specific regions for sequencing. This method enables a significantly higher assay throughput than what is realized by standard PCR-based approaches and allows for the inclusion of additional targets for relevant SARS-CoV-2 mutations of interest as needed.
Dr. Ellis will describe how his work at Fry Laboratories, in collaboration with Beckman Coulter Life Sciences, is using economical and nimble NGS-based assays to fill gaps in its capabilities as it works to reduce the impact of SARS-CoV-2.
He will also discuss how the combined capabilities across prokaryotic, eukaryotic, and viral detection using a unified NGS-based technology enabled by scalable solutions represents a new horizon in molecular microbiology.